Johnson Pharmacare (532154) Q4 25/26 earnings summary

Executive summary

• Audited financial results for the year ended March 31, 2026, show a significant net loss and negative cash flows from operations.

• The company operates primarily in investments and lending, with no physical inventory and significant inter-corporate loans.

Financial highlights

• Total income for FY26 was ₹158.10 lakhs, with a net loss of ₹5,573.39 lakhs, compared to a net loss of ₹58.38 lakhs in FY25.

• Basic and diluted EPS for FY26 stood at (1.01), down from (0.01) in FY25.

• Cash losses for FY26 amounted to ₹11,123.52 lakhs, a sharp increase from ₹58.38 lakhs in FY25.

• Net cash used in operating activities was ₹(5,756.74) lakhs for FY26.

Outlook and guidance

• The auditor notes significant doubt about the company’s ability to meet its liabilities as they fall due within one year.

• Management asserts the financial crisis is temporary and steps are being taken to improve the situation.